Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU

Amarin (AMRN) shares surged 27.3% following an exclusive long-term licensing and supply agreement with Recordati for its drug Vazkepa across 59 EU countries. The deal provides Amarin with an upfront payment of $25 million, up to $150 million in potential milestone payments, and supply-based royalties, while enabling approximately $70 million in EU cost savings over the next 12 months. This strategic move is expected to strengthen Amarin's cash position, accelerate its path to positive cash flow, and allow a greater focus on its profitable U.S. business, leveraging Recordati's established European commercialization capabilities for Vazkepa.

Analysis

Amarin's stock surged 27.3% following the announcement of an exclusive long-term licensing and supply agreement with Recordati for its sole marketed drug, Vazkepa, across 59 European countries. This strategic pivot is financially significant, providing an immediate $25 million upfront payment and the potential for up to $150 million in sales-based milestones. The deal effectively de-risks Amarin's European operations by transitioning to a leaner model, which is projected to generate approximately $70 million in cost savings over the next 12 months. This restructuring strengthens Amarin's financial position, which already included nearly $300 million in cash and no debt as of March-end, and accelerates its path to achieving positive cash flow. By leveraging Recordati's established cardiovascular commercial infrastructure in the EU, Amarin can now focus on its profitable and cash-generative U.S. business while participating in European growth through supply-based royalties. The long-term value is further underpinned by Vazkepa's patent protection in the EU until 2039, securing a durable, capital-light revenue stream. The market's positive reaction reflects this improved financial outlook and strategic clarity, contributing to the stock's 65.3% year-to-date rally against a declining industry benchmark.

Key Decisions for Investors

• Investors should recognize the Recordati deal as a significant de-risking event that improves Amarin's financial stability and accelerates its path to profitability, warranting a re-evaluation of the company's valuation.
• It is prudent to monitor the execution of the European commercialization by Recordati, as the achievement of sales targets is directly tied to the $150 million in potential milestone payments and will validate the partnership's success.
• Consider that this strategic shift towards a leaner, partnership-focused international model allows Amarin to concentrate resources on its core, profitable U.S. market, which could unlock further value and steady cash flow generation.